Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P23/00—Anaesthetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P23/00—Anaesthetics
  • A61P23/02—Local anaesthetics

Definitions

• This invention relates to a new therapeutic use for levobupivacaine or (S)-l- butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide, and to new formulations including it.
• Racemic bupivacaine is an effective long-acting local anaesthetic, and may be given as an epidural. However, racemic bupivacaine is cardiotoxic, having depressant electrophysiological and mechanical effects on the heart. It should therefore be used with caution in cardiac-compromised patients, and the use of high doses and high concentrations is contraindicated.
• CNS central nervous system
• This invention is based on two surprising observations. The first is that, whereas a large dose of bupivacaine may be fatal in sheep, the same dose of levobupivacaine is not. It is therefore possible to administer much larger amounts of levobupivacaine, safely. Without wishing to be bound by theory, it may be that, because a given dose of levobupivacaine takes longer to reach T,, ⁇ than the same dose of racemate, a higher amount of levobupivacaine may safely be administered, that provides anaesthesia.
• levobupivacaine exhibits a different pathic handling compared with bupivacaine. This manifests itself as a faster plasma clearance rate within 0-4 hours post-administration. Therefore, for major surgical procedures, where aberrant injection may occur, the risk of harming the patient is reduced due to faster clearance in the problematic phase.
• Typical blocks may be brachial plexus, axillary, supraclavicular block or interscalene. These procedures are characterised by the desire or need for deep sensory block and adequate motor block.
• levobupivacaine may be provided in solution, for infusion or injection, or for administration by any of the conventional means for obtaining a nerve or field block/local infiltration.
• levobupivacaine may also be useful in providing blocks in areas of the body where the risk of systemic exposure to the drug, and therefore CNS side-effects, is particularly high. Examples include open wounds and vascular areas, for instance using intercostal blocks for the latter.
• infusion into the body near the base of the limb may be appropriate.
• a regional or plexus block may also be used.
• no more than 0.5% w/v levobupivacaine may be used. This concentration may provide less motor block than a higher concentration, or the same concentration of racemate, when administered epidurally, e.g. for lower limb surgery. However, a higher concentration may increase depth and duration of sensory block.
• Levobupivacaine administered spinally has advantages, in terms of reduced neurotoxicity, over lignocaine (whether plain or hyperbaric formulations). Lignocaine must typically be administered at a concentration of 2-5%. Racemic bupivacaine is not widely used for spinal administration.
• unit doses may be in the form of ampoules, which may be made of any suitable material, e.g. glass or an appropriately impervious plastic material.
• Unit dosages comprising at least
• levobupivacaine 200 mg are new and can be used directly.
• the amount administered may be 3 to 5 mg/kg.
• levobupivacaine can be administered to a patient safely for at least 24 hours, often up to
• levobupivacaine can be administered with another drug such as fentanyl; see PCT/GB98/00658.
• the levobupivacaine used in the present invention is preferably substantially free of dextrobupivacaine, and is more preferably in at least 90%, and most preferably at least
• Study 1 The electrocardiological effects of bupivacaine and levobupivacaine were compared, in two groups of conscious, previously instrumented, adult sheep. Two cohorts of 7 animals were infused over 1 min with 6.25, 12.5, 18.75, 25 and 37.5 mg levobupivacaine and 12.5, 25 and 37.5 mg bupivacaine or over 3 min with 37.5, 50, 75, 100, 150 and 200 mg levobupivacaine and 37.5, 75, 100, 150 and 200 mg bupivacaine. Both drugs at doses of 75 mg were without significant electrocardiological effect.
• Fig. 1 and 2 of the accompanying drawings show baseline record of ECG (left), S-T segment change (centre) and multiform ventricular tachycardia (right) after i.v. infusion (40 ml, 3 min) of 100 mg bupivacaine and then of 200 mg levobupivacaine, in the same sheep.
• the aim of this study was to determine the lethal dose of each of the local anesthetics levobupivacaine (L), bupivacaine (B) and ropivacaine (R)as well as to compare their respective effects on the QRS interval of the precordial ECG. Prolongation of the QRS has been shown to correlate highly with in vitro cardiotoxicity of bupivacaine and lidocaine (Reiz et al, supra).
• a total of 27 animals were randomized to receive a dose response injection of L, B or R into the LAD.
• a blinded randomized protocol was used. All calculations and exclusions were made prior to disclosure of treatment.
• the doses of each agent were 0.375, 0.75, 1.5, 3.0, 4.0 mg etc., in increments of 1 mg till death occurred.
• Each dose was made up in a volume of 3 ml plus the dead space of the catheter (1.2 ml), injected over 10 sec. The time between doses was 5 min, or longer, if ECG, blood pressure or heart rate had not returned to pre-injection controls.
• a complete 12-lead ECG was recorded on optical disk for later analysis.
• Statistical analysis was by ANO VA, Dunnett's and the Mann-Whitney-U test. Power analysis was performed (0.85 to 1.00).
• the mean drug concentration producing a 50% reduction (CI-50) in cell shortening was calculated from cumulative dose-response curves. All data were analysed by an unpaired t-test (for control data comparison) or one-way ANOVA (for comparison between drug groups), assuming a Gaussian distribution. The most important observation was that, on washout of local anaesthetic from myocardium with drug-free perfusate, the recovery of contractility following levobupivacaine was significantly greater than that for bupivacaine (P ⁇ 0.05) in both cardiac mycocytes (see Fig. 3) and guinea-pig papillary muscle (see Fig. 4). Therefore, there is a potential for better reversibility after intravascular injection of levobupivacaine. Study 5

Landscapes

• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Anesthesiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Peptides Or Proteins (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Ultra Sonic Daignosis Equipment (AREA)
• Electrotherapy Devices (AREA)
• Apparatus For Radiation Diagnosis (AREA)

Priority Applications (7)

Applications Claiming Priority (6)

Publications (2)

Family

ID=27268945

Family Applications (1)

Country Status (12)

Cited By (1)

Families Citing this family (26)

Family Cites Families (6)

• 1998
  • 1998-07-21 WO PCT/GB1998/002170 patent/WO1999004772A2/en not_active Ceased
  • 1998-07-21 ES ES98935176T patent/ES2198731T3/es not_active Expired - Lifetime
  • 1998-07-21 DK DK98935176T patent/DK0998287T3/da active
  • 1998-07-21 EP EP98935176A patent/EP0998287B1/en not_active Expired - Lifetime
  • 1998-07-21 CA CA002294921A patent/CA2294921C/en not_active Expired - Lifetime
  • 1998-07-21 BR BR9802537A patent/BR9802537A/pt not_active Application Discontinuation
  • 1998-07-21 PT PT98935176T patent/PT998287E/pt unknown
  • 1998-07-21 DE DE69814394T patent/DE69814394T2/de not_active Expired - Lifetime
  • 1998-07-21 JP JP2000503831A patent/JP2001510795A/ja active Pending
  • 1998-07-21 AU AU84528/98A patent/AU739510B2/en not_active Expired
  • 1998-07-21 AT AT98935176T patent/ATE239474T1/de active
  • 1998-07-22 US US09/120,822 patent/US6069155A/en not_active Expired - Lifetime
• 2001
  • 2001-10-01 US US09/969,412 patent/US6514994B2/en not_active Expired - Fee Related

Also Published As

Similar Documents

Legal Events